Lipopolysaccharide (LPS) Test – Endotoxin, Gut Barrier & Inflammation

Lipopolysaccharide (LPS) is an endotoxin found in the outer membrane of gram-negative bacteria in the gut. When the intestinal barrier is compromised (leaky gut), LPS can translocate into the bloodstream, triggering systemic inflammation. Elevated blood LPS is associated with chronic disease, metabolic endotoxemia, and various inflammatory conditions.

How to interpret your LPS test results

A lipopolysaccharide (LPS) test measures bacterial endotoxin in blood, plasma, or other body fluids. LPS comes from the outer membrane of gram-negative bacteria, so its appearance in circulation suggests bacterial fragments have crossed the gut barrier, entered through an infection site, or contaminated a parenteral product. Outside of acute infection workups, most LPS measurement today happens in research and serotyping rather than as a routine clinical test.

No single reference range applies universally to blood LPS. Values depend on the sample type, the assay (LAL, ELISA, biosensor), and the laboratory’s own calibration. The LAL assay reports in endotoxin units per milliliter (EU/mL); sandwich ELISA kits such as ENDOLisa quantify in the 0.05–500 EU/mL range. Anti-LPS antibody tests are reported as titers and reflect cumulative exposure rather than current circulating load.

What the assay readout actually represents

Because lipid A is highly conserved across gram-negative species, an LPS-positive result tells you endotoxin was detected — not which organism produced it. The intensity of the host immune response also depends on the structural variation of lipid A between species, so the same nominal EU/mL value can mean different things biologically depending on the source bacteria.

Two practical caveats matter. First, LPS is environmentally ubiquitous; endogenous endotoxins on glassware, plastics, or reagents can cause false positives if pyrogen-free handling is not strict. Second, antibody-based ELISAs only cover strains for which a purified antigen exists, so a negative antibody result does not rule out exposure. Repeat or confirmatory testing is common when results carry clinical weight.

Symptoms and conditions linked to elevated LPS

Elevated LPS produces symptoms that fall into two broad patterns: an acute high-dose response that looks like infection or sepsis, and a chronic low-dose response that overlaps with metabolic and inflammatory disease.

Acute endotoxemia

When large amounts of LPS reach the bloodstream during severe gram-negative infection, the immune system mounts an aggressive response. As little as 1 to 2 mg of LPS entering intravenously can be lethal. The clinical picture of full endotoxic shock can include:

• Fever and temperature fluctuations
• Leukopenia (low white-cell count)
• Tachycardia and tachypnea (rapid heart rate and breathing)
• Hypotension from arterial and venous dilation
• Activation of the coagulation cascade and disseminated intravascular coagulation
• Damage to blood vessels and inadequate tissue perfusion

LPS underlies many clinical manifestations of gram-negative infection, including meningococcal disease and Waterhouse-Friderichsen syndrome caused by Neisseria meningitidis. Acute presentations are medical emergencies, diagnosed through the broader sepsis workup rather than by an LPS number alone.

Chronic low-grade exposure

The chronic pattern is harder to feel directly. Persistently low but elevated circulating LPS — often described as metabolic endotoxemia — has been associated with metabolic syndrome, type 2 diabetes, heart disease, and liver disease. Low-dose LPS exposure has also been correlated with autoimmune conditions and allergies. In infants, Bacteroides-derived LPS has been linked to food allergy and anti-insulin antibodies, viewed as early signs of immune dysfunction. These are associations, not diagnostic criteria — an LPS measurement alone cannot establish that a chronic condition is caused by endotoxemia.

LPS, metabolic endotoxemia, and chronic disease

Metabolic endotoxemia describes a state where blood LPS sits well below the levels that cause septic shock yet is still high enough to drive low-grade systemic inflammation. The same TLR4/CD14/MD2 receptor pathway that mediates acute infection runs at lower, sustained intensity, producing chronic inflammatory signaling. Elevated circulating LPS has been associated with metabolic conditions and chronic disease, and is widely measured in animal and human research.

Why the same LPS number can mean different things

Not all LPS molecules trigger the same immune response. The lipid A portion is mutable, and structural differences between species produce different intensities of host immunity. Hexa-acylated, bisphosphorylated lipid A from E. coli and Salmonella is highly immunogenic, while lipid A from Yersinia pestis and other less-canonical forms can be far less so. Two patients with identical EU/mL readings can mount very different responses depending on which gut species produced the endotoxin.

LPS also disturbs lipid metabolism. It binds to HDL and LDL particles, predisposes to hypercholesterolemia and dyslipidemia, and has been implicated in non-alcoholic fatty liver disease. Through effects on membrane apo E and amyloid-beta interactions, LPS has been linked to neurological degeneration in research models. Markers used alongside LPS in this space include hs-CRP for systemic inflammation and IL-6 and TNF-alpha for cytokine activity, since these downstream signals are what the TLR4 cascade ultimately produces.

LPS vs. LBP vs. anti-LPS antibodies: which test is right?

Three blood markers relate to LPS exposure but answer different questions. The choice is less about which is “best” and more about which window of biology you need.

Direct LPS quantification (typically by LAL) is the historical reference and the standard used in pharmaceutical pyrogen testing. LBP is often used as a more stable proxy in metabolic endotoxemia research because circulating LPS itself is rapidly bound and cleared. Anti-LPS antibody testing reflects adaptive immunity, so it captures cumulative exposure over time but cannot detect a new pathogen exposure, and is limited to strains whose antigens have been isolated.

Related markers in gut-barrier and inflammation research include zonulin as a marker of intestinal permeability and gut microbiota testing to characterize the community producing the endotoxin. None substitutes for an LPS measurement, but they help contextualize a result.

How LPS is detected: LAL, ELISA, and newer biosensors

LPS measurement methods fall into several overlapping categories — in vivo and in vitro assays, modified immunoassays, biological assays, and chemical assays. The choice depends on sensitivity needs, sample type, and whether species-level discrimination is required.

The LAL assay

The Limulus Amoebocyte Lysate (LAL) assay is the gold standard for lipid A detection. It exploits a protease cascade from horseshoe crab amoebocytes that clots in the presence of endotoxin. Variants use chromogenic, turbidimetric, or viscometric readouts to quantify clotting. LAL has been validated across many sample types — urine, cerebrospinal fluid, synovial fluid, ascites, vaginal and cervical fluids, bronchoalveolar lavage, and even seawater. Its main limitations are susceptibility to chemical interference and an inability to distinguish between LPS serogroups.

ELISA and antibody-based methods

Standard ELISAs struggle with LPS because its amphipathic nature produces inconsistent plate binding and variable epitope conformations, hurting sensitivity and reproducibility. Enhanced sandwich ELISAs address this — ENDOLisa achieves sensitivity between 0.05 and 500 EU/mL. Antibody-format ELISAs flip the design: the plate is coated with LPS antigen to pull down anti-LPS IgA, IgG, or IgM from serum. These assays suit population-level epidemiology and exposure history but cannot detect initial pathogen exposure and only cover strains with isolated antigens.

Biosensors and chemical detection

Newer sensing platforms use natural LPS carriers (LBP, HDL, LDL) or synthetic ligands (aptamers, peptides, metal-cation complexes) to capture LPS, with electrochemical or fluorescent readouts. Aptamers attached to gold nanoparticles, read by electrochemical impedance spectroscopy, can reach a detection limit around 0.1 pg/mL. These platforms achieve picogram-to-femtomolar sensitivity but, like LAL, cannot discriminate between serogroups. Contamination is the universal pitfall: environmental endotoxins on glassware, plastics, and reagents can produce false positives, so pyrogen-free handling is essential regardless of assay choice.

When to talk to your doctor

LPS testing is not part of a routine primary-care panel, and an isolated number cannot diagnose chronic disease on its own. Talk to a clinician promptly in these situations:

• You have signs of acute systemic infection — high fever, rapid heart rate, rapid breathing, low blood pressure, confusion, or poor circulation — and seek emergency care. These features overlap with the endotoxemia and septic-shock picture in clinical references.
• You have a known or suspected gram-negative infection (urinary, abdominal, respiratory, or post-surgical) that is not improving on treatment. LPS-driven inflammation is the mechanism behind much of the symptomatology of these infections.
• You have persistent unexplained chronic symptoms — fatigue, joint pain, recurrent loose stools, post-meal malaise — and a private test reports elevated LPS or anti-LPS antibodies. A clinician can help interpret the result, repeat testing if warranted, and rule out gram-negative infection before any chronic-disease attribution.
• You are managing a metabolic or cardiovascular condition (type 2 diabetes, NAFLD, dyslipidemia) and want to understand whether endotoxemia research is relevant to your care. These associations are real in the literature but do not yet drive standard treatment decisions.
• Your result was ordered through a direct-to-consumer functional or research panel. Bring the full report to your doctor; assay, units, and contamination controls all affect how the number should be read.

Self-treating based on an LPS number alone is not advised; the evidence base for routine LPS-driven interventions is still being established.

Frequently asked questions

What is an LPS blood test for?

An LPS blood test detects bacterial endotoxin in circulation. It is most established clinically in pharmaceutical pyrogen testing and infection research. In consumer and functional settings it is used to investigate gut-barrier dysfunction and metabolic endotoxemia, though reference ranges are not standardized.

What are the symptoms of high levels of LPS?

Acutely high LPS causes fever, leukopenia, rapid heart rate, rapid breathing, low blood pressure, and coagulation problems — the picture of endotoxic shock. Chronically elevated low-grade LPS has been associated with metabolic syndrome, type 2 diabetes, fatty liver disease, autoimmune conditions, and allergies.

What foods are high in LPS?

LPS is found wherever gram-negative bacteria live. Many food products, supplements, and even probiotics can contain gram-negative bacterial fragments or intact LPS. For healthy people, digestion handles dietary LPS, but it can represent a risk in patients with gastrointestinal disease where barrier function is impaired.

Is LPS the same as endotoxin?

Yes — LPS is the canonical bacterial endotoxin, and the terms are used interchangeably in clinical and research literature. Strictly speaking, the lipid A portion of LPS is the bioactive endotoxin component recognized by the immune system.

What is the difference between LPS and LBP testing?

An LPS test measures the endotoxin molecule, usually by LAL or ELISA. LBP (lipopolysaccharide-binding protein) is the serum carrier that delivers LPS to the CD14 receptor on immune cells. Because circulating LPS is rapidly cleared, LBP is often used as a more stable indirect marker of cumulative endotoxin exposure in research.

What does LPS IgG mean?

Anti-LPS IgG measures antibodies the adaptive immune system has produced against LPS antigens. It reflects past or ongoing exposure rather than a current acute event and cannot detect a first exposure. It is limited to strains whose antigens have been isolated and is used mainly for epidemiology.

Is there a blood test for leaky gut or IBS using LPS?

No validated LPS-based blood test diagnoses leaky gut, IBS, or related functional GI conditions. LPS measurement appears in research on intestinal permeability and metabolic endotoxemia, but its clinical use is still primarily infection serotyping and pyrogen testing. A clinician can advise on validated GI workups for your symptoms.

References

• Peer-reviewed reference
• PubMed (U.S. National Library of Medicine, NIH)

Last reviewed: 2026-05-13